Cochlear Ltd - Company Profile
Powered by
All the data and insights you need on Cochlear Ltd in one report.
- Save hours of research time and resources with
our up-to-date Cochlear Ltd Strategy Report
- Understand Cochlear Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Cochlear Ltd (Cochlear) is a medical device company that offers implantable hearing solutions to the customers. It develops, manufactures, and markets electronic implantable hearing devices. The company’s products are suited for people with hearing loss caused by ear nerve damage. Its major products include cochlear implant systems, bone conduction systems, acoustic implants, bone anchored prosthetics and wireless accessories including wireless mini microphone, wireless phone clip and wireless television streamer. It has manufacturing facilities and regional distribution centers in North America and Europe. The company conducts its operations in the Asia-Pacific, Americas, the Middle East and Europe. The company markets its products through subsidiaries, local offices, distributors and agents. Cochlear is headquartered in Sydney, New South Wales, Australia.
Cochlear Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Bone Anchored Implants: | Nucleus |
Baha System and Accessories: | ESPrit |
Titanium Implant and Osseointegration | Softip |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In April, the company received approval from the US FDA to extend the utilization of its Osia System to children as young as five years old. |
2023 | New Products/Services | In August, the company launched its next-generation active bone conduction system, the Cochlear Osia System. |
2022 | Regulatory Approval | In November, the company received the US Food and Drug Administration approval for the Cochlear Nucleus 8 Sound Processor. |
Competitor Comparison
Key Parameters | Cochlear Ltd | Sonova Holding AG | Demant A/S | Rion Co Ltd | GN ReSound Pty. Ltd |
---|---|---|---|---|---|
Headquarters | Australia | Switzerland | Denmark | Japan | Australia |
City | Sydney | Staefa | Smoerum | Kokubunji-Shi | - |
State/Province | New South Wales | - | - | Tokyo | - |
No. of Employees | 4,800 | 17,608 | 21,623 | 998 | - |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Alison Deans | Chairman | Executive Board | 2021 | - |
Dig Howitt | Director; Chief Executive Officer; President; Managing Director | Executive Board | 2018 | - |
Stuart Sayers | Chief Financial Officer | Senior Management | 2021 | - |
Karen O’Driscoll | Chief Information Officer | Senior Management | 2023 | - |
Jan Janssen | Chief Technology Officer | Senior Management | 2017 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer